The Cancer Clinical Library Database (CCLD) from the Korea-Clinical Data Utilization Network for Research Excellence (K-CURE) Project
- Author:
Sangwon LEE
1
;
Yeon Ho CHOI
;
Hak Min KIM
;
Min Ah HONG
;
Phillip PARK
;
In Hae KWAK
;
Ye Ji KANG
;
Kui Son CHOI
;
Hyun-Joo KONG
;
Hyosung CHA
;
Hyun-Jin KIM
;
Kwang Sun RYU
;
Young Sang JEON
;
Hwanhee KIM
;
Jip Min JUNG
;
Jeong-Soo IM
;
Heejung CHAE
Author Information
- Publication Type:Special Article
- From:Cancer Research and Treatment 2025;57(1):19-27
- CountryRepublic of Korea
- Language:English
- Abstract: The common data model (CDM) has found widespread application in healthcare studies, but its utilization in cancer research has been limited. This article describes the development and implementation strategy for Cancer Clinical Library Databases (CCLDs), which are standardized cancer-specific databases established under the Korea-Clinical Data Utilization Network for Research Excellence (K-CURE) project by the Korean Ministry of Health and Welfare. Fifteen leading hospitals and fourteen academic associations in Korea are engaged in constructing CCLDs for 10 primary cancer types. For each cancer type-specific CCLD, cancer data experts determine key clinical data items essential for cancer research, standardize these items across cancer types, and create a standardized schema. Comprehensive clinical records covering diagnosis, treatment, and outcomes, with annual updates, are collected for each cancer patient in the target population, and quality control is based on six-sigma standards. To protect patient privacy, CCLDs follow stringent data security guidelines by pseudonymizing personal identification information and operating within a closed analysis environment. Researchers can apply for access to CCLD data through the K-CURE portal, which is subject to Institutional Review Board and Data Review Board approval. The CCLD is considered a pioneering standardized cancer-specific database, significantly representing Korea’s cancer data. It is expected to overcome limitations of previous CDMs and provide a valuable resource for multicenter cancer research in Korea.
